A Phase 1b, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of Orally Administered Dapansutrile Capsules in Subjects With NYHA II-III Systolic Heart Failure
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Dapansutrile (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Olatec Therapeutics
- 26 Aug 2019 Planned End Date changed from 28 Feb 2019 to 28 Feb 2020.
- 26 Aug 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.